Is it Possible to Increase pCR in the Neoadjuvant Treatment With a Dose-Dense/Sequential Combination?

Abstract

These results show a highly effective regimen in terms of pCR with a good toxicity profile in the neoadjuvant treatment of patients with breast cancer. The addition of trastuzumab increased pCR rate in Her2+ tumors.